Aardvark Therapeutics (AARD) Non Operating Income (2024 - 2026)
Aardvark Therapeutics (AARD) posted Non Operating Income of $876000.0 for Q1 2026, down 20.8% sequentially from $1.1 million in Q4 2025, and down 24.48% YoY from $1.2 million in Q1 2025.
Aardvark Therapeutics (AARD) Non Operating Income (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Non Operating Income for 3 years, with the latest figure at $876000.0 in Q1 2026.
- Quarterly Non Operating Income fell 24.48% year-over-year to $876000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 million (up 44.17% YoY) and the FY2025 annual result came in at $5.1 million, up 133.68% from the prior year.
- Non Operating Income fell to $876000.0 in Q1 2026 per AARD's latest filing, from $1.1 million in the prior quarter.
- Over five years, Non Operating Income peaked at $1.5 million in Q2 2025 and troughed at -$7000.0 in Q1 2024.
- A 3-year average of $911888.9 and a median of $909000.0 in 2024 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2025 and 2026: Non Operating Income jumped 16671.43% in 2025, then slipped 24.48% in 2026.
- Over 3 years, Non Operating Income stood at $671000.0 in 2024, then surged by 64.83% to $1.1 million in 2025, then dropped by 20.8% to $876000.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $876000.0, $1.1 million, and $1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Aardvark Therapeutics | 147.46 Mn | 73.54 Mn | - | 697,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 697,000.00 |
| Mar 31, 2026 | 876,000.00 |
| Dec 31, 2025 | 1.11 Mn |
| Sep 30, 2025 | 1.39 Mn |
| Jun 30, 2025 | 1.48 Mn |
| Mar 31, 2025 | 1.16 Mn |
| Dec 31, 2024 | 671,000.00 |
| Sep 30, 2024 | 909,000.00 |
| Jun 30, 2024 | 624,000.00 |
| Mar 31, 2024 | -7,000.00 |